Literature DB >> 29345111

Association between hepatitis C infection in Thai patients with oral lichen planus: A case-control study.

Trin Manomaivat1, Surawut Pongsiriwet2, Chatsri Kuansuwan2, Wacharaporn Thosaporn2, Kathawut Tachasuttirut1, Anak Iamaroon2.   

Abstract

AIM: The aim of the present study was to investigate the prevalence of hepatitis C virus (HCV) infection and evaluate liver enzyme levels in patients from upper northern Thailand with oral lichen planus (OLP).
METHODS: A case-control study of 101 patients with OLP and 101 patients without OLP was conducted. Peripheral blood was taken from each patient and screened for anti-HCV antibody using immunochromatography. Positive samples were further confirmed using chemiluminescent microparticle immunoassay (CMIA) and reverse transcription-polymerase chain reaction. In addition, liver enzyme levels, alanine transaminase, aspartate transaminase, and alkaline phosphatase were evaluated using spectrophotometry.
RESULTS: Immunochromatography and CMIA revealed that nine patients with OLP (8.9%) were positive for anti-HCV antibodies, whereas only one patient without OLP was HCV positive (odds ratio = 9.78). All patients who were HCV positive had significantly higher liver enzyme levels than patients who were HCV negative.
CONCLUSIONS: The results of the present study indicated that OLP in certain patients was significantly associated with HCV. This could warrant screening for HCV-infected patients with OLP in Thailand.
© 2018 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  case-control study; hepatitis c virus; liver enzyme; northern Thailand; oral lichen planus

Mesh:

Year:  2018        PMID: 29345111     DOI: 10.1111/jicd.12316

Source DB:  PubMed          Journal:  J Investig Clin Dent        ISSN: 2041-1618


  1 in total

1.  Sample Size Calculation Guide - Part 3: How to Calculate the Sample Size for an Independent Case-control Study.

Authors:  Nadien Khaled Fahim; Ahmed Negida; Ahmed Khaled Fahim
Journal:  Adv J Emerg Med       Date:  2019-02-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.